Yahoo Malaysia Web Search

Sign In

Search results

  1. verzenio.lilly.comVerzenio® (abemaciclib) - HR+, HER2- Early and Metastatic Breast...

    Verzenio (abemaciclib) is a treatment for both HR+, HER2-, high risk, node positive early breast cancer and for certain types of HR+, HER2- metastatic breast cancer.

  2. Videos

    View all

  3. www.breastcancer.org › treatment › targeted-therapyVerzenio (Abemaciclib): What to Expect, Side Effects, and More

    Verzenio is a pill that can be used to treat both early-stage and advanced-stage hormone receptor-positive HER2-negative breast cancer. Reviewed by 1 medical adviser. Sections. How Verzenio works. What to expect during Verzenio treatment. Verzenio side effects. Real patient reviews. Paying for Verzenio. Advertisement.

  4. en.wikipedia.org › wiki › AbemaciclibAbemaciclib - Wikipedia

    Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in October ...

  5. Images

    • VERZENIO™ (abemaciclib) Available in Canada for Metastatic Breast ...
    • VERZENIO 150 mg Tablets ( Abemaciclib 150 mg ) 14 tablets
    • Verzenio 150mg (Abemaciclib) - redfarma
    • Verzenio® (abemaciclib): Expanded Indication Approved by the U.S. FDA ...

    View all

  6. verzenio.lilly.com › early-breast-cancer › what-is-verzenioWhat is Verzenio® for Early Breast Cancer | Verzenio...

    How Verzenio works. Verzenio is a CDK4 & 6 inhibitor used to treat HR+, HER2–, node-positive, early breast cancer with a high risk of coming back as determined by your doctor. Verzenio works to block specific proteins called CDK4 & CDK6. CDK4 & 6 proteins help control how fast cells grow.

  7. www.fda.gov › drugs › resources-information-approved-drugsFDA expands early breast cancer indication for abemaciclib with...

    On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant ...

  8. www.fda.gov › drugs › resources-information-approved-drugsFDA approves abemaciclib with endocrine therapy for early breast...

    The recommended abemaciclib starting dose is 150 mg taken twice daily in combination with tamoxifen or an aromatase inhibitor until completion of 2 years of treatment or until disease...

  9. www.fda.gov › news-events › press-announcementsFDA approves new treatment for certain advanced or metastatic...

    The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2 ...